Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells $445,680.62 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 16,142 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $27.61, for a total value of $445,680.62. Following the sale, the chief marketing officer owned 16,142 shares of the company’s stock, valued at approximately $445,680.62. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The shares were sold at an average price of $29.90, for a total value of $436,809.10.

Maze Therapeutics Trading Down 1.8%

NASDAQ MAZE traded down $0.49 during trading hours on Friday, hitting $27.18. 230,651 shares of the company’s stock were exchanged, compared to its average volume of 663,051. The stock has a 50-day simple moving average of $27.73 and a 200 day simple moving average of $33.08. Maze Therapeutics, Inc. has a 1-year low of $12.81 and a 1-year high of $53.65. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -10.79 and a beta of 2.21. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). On average, equities analysts forecast that Maze Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Royal Bank of Canada raised its holdings in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Maze Therapeutics during the 4th quarter valued at about $39,000. Ameritas Investment Partners Inc. increased its holdings in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Maze Therapeutics during the 4th quarter worth approximately $43,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Maze Therapeutics in the second quarter worth approximately $48,000.

Key Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: BTIG issued a Buy rating. The endorsement adds to the constructive analyst view of Maze’s pipeline and could support investor confidence. Maze Therapeutics Earns Buy Rating from BTIG Research
• Positive Sentiment: Maze strengthened its board with two experienced executives. Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., bring extensive clinical, pharmaceutical, partnering, and commercialization expertise. Management also highlighted additional MZE829 data in late 2026 or early 2027, initial MZE782 data in 2027, and additional trial starts next year. Maze Therapeutics Announces Appointments to Its Board of Directors
• Positive Sentiment: HC Wainwright raised all of its reported EPS forecasts. Estimates improved for third-quarter 2026, fourth-quarter 2026, and fiscal years 2026 through 2030. For example, FY2026 EPS was revised to a loss of $2.81 from $2.96, while FY2030 was revised to a loss of $0.72 from $0.74, indicating expectations for a somewhat faster reduction in losses over time.
• Neutral Sentiment: Maze reported second-quarter 2026 financial results and recent business highlights. The available report headline does not provide the detailed financial figures, so the earnings release’s impact cannot be fully assessed from the supplied information. Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
• Negative Sentiment: Maze remains unprofitable. HC Wainwright’s revised forecasts still call for substantial losses through 2030, and its FY2026 estimate of a $2.81 loss is slightly worse than the $2.73 consensus forecast.
• Negative Sentiment: Reported insider activity is a concern. Company insiders have recorded sales but no purchases during the past six months, potentially weighing on sentiment.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on MAZE shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, BTIG Research reissued a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.